These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35763645)

  • 41. Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.
    Wang X; Teer JK; Tousignant RN; Levin AM; Boulware D; Chitale DA; Shaw BM; Chen Z; Zhang Y; Blakeley JO; Acosta MT; Messiaen LM; Korf BR; Tainsky MA
    Genes Chromosomes Cancer; 2018 Jan; 57(1):19-27. PubMed ID: 28891274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women.
    Fu F; Zhang D; Hu L; Sundaram S; Ying D; Zhang Y; Fu S; Zhang J; Yao L; Xu Y; Xie Y
    Cancer Biol Med; 2021 Oct; 19(2):253-62. PubMed ID: 34606182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy.
    Urbina-Jara LK; Rojas-Martinez A; Martinez-Ledesma E; Aguilar D; Villarreal-Garza C; Ortiz-Lopez R
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31658756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
    Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and genetic characterization of hereditary breast cancer in a Chinese population.
    Jian W; Shao K; Qin Q; Wang X; Song S; Wang X
    Hered Cancer Clin Pract; 2017; 15():19. PubMed ID: 29093764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular characteristics of young-onset colorectal cancer in Vietnamese patients.
    Do MD; Nguyen TH; Le KT; Le LHG; Nguyen BH; Le KT; Doan TPT; Ho CQ; Nguyen HN; Tran TD; Vu HA
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):678-685. PubMed ID: 35098669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
    Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer.
    Zografos E; Andrikopoulou A; Papatheodoridi AM; Kaparelou M; Bletsa G; Liontos M; Dimopoulos MA; Zagouri F
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
    Sahin I; Saat H
    Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
    [No Abstract]   [Full Text] [Related]  

  • 55. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
    Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
    Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
    Ricks-Santi L; McDonald JT; Gold B; Dean M; Thompson N; Abbas M; Wilson B; Kanaan Y; Naab TJ; Dunston G
    Ethn Dis; 2017; 27(2):169-178. PubMed ID: 28439188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
    Liu Y; Wang H; Wang X; Liu J; Li J; Wang X; Zhang Y; Bai Z; Zhou Q; Wu Y; Shen Y; Weng X; Liu F; Guo J; Di L; Gires O; Zhang Z; Chen Y; Wang H
    J Hematol Oncol; 2021 Jan; 14(1):18. PubMed ID: 33461583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.